Richmond NJ, Quesada UK

Language: Spanish
References: 8
Page: 28-39
PDF size: 572.74 Kb.

ABSTRACT

Introduction: The objective of the study is to describe the results of the application of this therapy in patients admitted to the Intensive Care Unit of the Dr. Rafael Ángel Calderón Guardia Hospital.
Materials and Methods: This was an observational, descriptive and retrospective study conducted by reviewing records of patients over 18 years admitted to the ICU, who underwent apheresis therapy. Proceeded to fill the data collection sheet developed for this purpose. 50 patients who met the inclusion criteria were included and admitted to the ICU in the study period.
Results: of all patients admitted to apheresis therapy, 40% were cases of neurological diseases, of these, 20% had Guillain-Barré syndrome, 30% have hematologic diseases (mainly autoimmune hemolytic anemia), 18% of the admissions to the ICU were by non-biliary pancreatitis associated with severe hypertriglyceridemia and the rest were reported by rheumatologic diseases. 80% of admitted patients received one to seven sessions of apheresis independent of the pathology that require the ICU admission. At admission to the ICU, 96% of the patients had neurological involvement, being progressive motor weakness the parameter more reported in 82% of cases, 86 % of the admissions had respiratory compromise, which require ventilator support, and 92% of patients with renal involvement required some form of renal support. 84% of patients were discharged from the ICU with neurological involvement, being progressive motor weakness the parameter with greater benefit, with 54%. 98% of the patients discharged continued with ventilatory support and 94% continued with some form of renal support. Forty- five patients (90%) were admitted with hematological compromise, at discharge from the unit, thirty-three patients (66%) showed improvement with respect to the admission. As for the renal function of these patients, 8 of them admitted, corresponding to 16 %, had creatinine levels > 2 mg / dl, and at discharge, seven patients (14%) maintained the same income levels. The average hospital stay was 90.7 days, with a median of 36.5 days.
Conclusions: 60% of patients admitted to the ICU for apheresis therapy correspond to neurological disease, being the most prevalent etiology Guillain-Barré syndrome. 30% admitted for hematological pathology require apheresis and 18% for non-biliary pancreatitis secondary to severe hypertriglyceridemia. Improvement was found in clinical and laboratory parameters in most of the criteria for admission of patients when compare themselves to discharge from the unit.

REFERENCES

1. Balogun R Kaplan A Ward D et al. Clinical Applications of Therapeutic Apheresis. Journal of Clinical Apheresis. 2010;25:250- 264.

2. Ewald N Hardt P Hans-Ulrich K. Severe hypertriglyceridemia and pancreatitis: presentation and management. Current Opinion in Lipidology. 2009;20:497–504.

3. McLeod B. Evidence based therapeutic apheresis in autoimmune and other hemolytic anemia. Current Opinion in Hematology. 2007;14:647–654.

4. Nguyen T Kiss J Goldman J. The Role of Plasmapheresis in Critical Illness. Critical Care Clinics. 2012;28:453–468.

5. Sanchez A Ward D. Therapeutic Apheresis for Renal Disorders. Seminars in Dialysis. 2012;25:119-131.

6. Szczepiorkowski Z Winters J Bandarenko N et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence- Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. Journal of Clinical Apheresis. 2010;25:83-177.

7. Okafor C Ward D Mokrzycki M et al. Introduction and Overview of Therapeutic Apheresis. Journal of Clinical Apheresis. 2010;25:240-249.

8. Winters JL. Apheresis Medicine State of art in 2010: American Society for Apheresis fifth special edition of the Journal of Clinical Apheresis. Journal of Clinical Apheresis. 2011;26(5):239-242.